

Annelie Liljegren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3201760/publications.pdf>

Version: 2024-02-01

19
papers

1,051
citations

759055

12
h-index

839398

18
g-index

19
all docs

19
docs citations

19
times ranked

3039
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-mastectomy radiation therapy with or without implant-based reconstruction is safe in terms of clinical target volume coverage and survival – A matched cohort study. <i>Radiotherapy and Oncology</i> , 2019, 131, 229-236.	0.3	11
2	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	0.9	148
3	Safety of fertility preservation in women with breast cancer. <i>Breast</i> , 2019, 43, 149.	0.9	0
4	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
5	Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 655-666.	1.1	2
6	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	2.9	12
7	Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 761-769.	1.1	45
8	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
9	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
10	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
11	Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. <i>British Journal of Cancer</i> , 2016, 115, 1400-1407.	2.9	22
12	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
13	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
14	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	0.9	195
15	Physical therapy after prophylactic mastectomy with breast reconstruction: A prospective randomized study. <i>Breast</i> , 2014, 23, 357-363.	0.9	7
16	No difference in dose distribution in organs at risk in postmastectomy radiotherapy with or without breast implant reconstruction. <i>Radiation Oncology</i> , 2014, 9, 14.	1.2	15
17	Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 791-798.	1.1	42
18	Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. <i>Breast</i> , 2009, 18, 259-262.	0.9	13

#	ARTICLE	IF	CITATIONS
19	MSI Test to Distinguish between HNPCC and Other Predisposing Syndromes â€” of Value in Tailored Surveillance. Disease Markers, 2004, 20, 259-267.	0.6	1